The cover shows a section of a tumor biopsy from mice with the SW1 melanoma, which were treated with an anti-CTLA4/PD-1/CD137 mAb combination. Immunohistochemical staining shows a dramatic decrease of tumor-infiltrating CD19 cells. For details, see the article by Dai and colleagues on page 1127 of this issue.